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Convection enhanced delivery (CED) infuses drugs directly into brain tissue. Needle
insertion is required and results in a stab wound injury (SWI). Subsequent secondary
injury involves the release of inflammatory and apoptotic cytokines, which have dramatic
consequences on the integrity of damaged tissue, leading to the evolution of a
pericontusional-damaged area minutes to days after in the initial injury. The present
study investigated the capacity for arctigenin (ARC) to prevent secondary brain injury
and the determination of the underlying mechanism of action in a mouse model of
SWI that mimics the process of CED. After CED, mice received a gavage of ARC
from 30 min to 14 days. Neurological severity scores (NSS) and wound closure
degree were assessed after the injury. Histological analysis and immunocytochemistry
were used to evaluated the extent of brain damage and neuroinflammation. Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was used to detect
universal apoptosis. Enzyme-linked immunosorbent assays (ELISA) was used to test
the inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-10)
and lactate dehydrogenase (LDH) content. Gene levels of inflammation (TNF-α, IL-6,
and IL-10) and apoptosis (Caspase-3, Bax and Bcl-2) were detected by reverse
transcription-polymerase chain reaction (RT-PCR). Using these, we analyzed ARC’s
efficacy and mechanism of action. Results: ARC treatment improved neurological
function by reducing brain water content and hematoma and accelerating wound
closure relative to untreated mice. ARC treatment reduced the levels of TNF-α and
IL-6 and the number of allograft inflammatory factor (IBA)- and myeloperoxidase (MPO)-
positive cells and increased the levels of IL-10. ARC-treated mice had fewer TUNEL+
apoptotic neurons and activated caspase-3-positive neurons surrounding the lesion
than controls, indicating increased neuronal survival. Conclusions: ARC treatment
confers neuroprotection of brain tissue through anti-inflammatory and anti-apoptotic
effects in a mouse model of SWI. These results suggest a new strategy for promoting
neuronal survival and function after CED to improve long-term patient outcome.
Keywords: arctigenin, stab wound injury, inflammation, apoptosis, convection enhanced delivery, traumatic brain
injury
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INTRODUCTION
Traumatic brain injury (TBI) is acquired from an external
force, which can inflict devastating effects to the brain tissue,
vasculature and neighboring neuronal cells (Logsdon et al., 2015).
CED infuses drugs directly into brain tissue (Casanova et al.,
2014a), which can result in stab wound injury (SWI), which is
a type of TBI.
The success of neurological disorder treatment depends on
effective techniques that deliver drugs to the central nervous
system (CNS). However, the blood–brain barrier (BBB) prevents
passive passage of the majority of large molecules from the
bloodstream into the extracellular space, so systemic delivery can
be problematic (Abbott and Romero, 1996; Nicholson, 2001).
CED is a technique that delivers therapeutic drugs directly to the
CNS, bypassing the BBB (Bobo et al., 1994). In CED, a needle
is inserted directly into the brain, and drug infusate is delivered
at controlled flow rates into the nidus. With convection as the
dominant transport mechanism, this technique can improve local
delivery and absorption by providing larger distribution volumes
than systemic delivery methods (Bobo et al., 1994; Casanova et al.,
2014a). While CED provides a new and effective method for the
treatment of nervous system diseases, at the same time, it will
cause the injury in the treatment process of insertion.
Convection enhanced delivery requires the surgical insertion
of a needle into brain tissue, and this results in SWI. The primary
damage of SWI is tissue tear, cell breakage and hemorrhage.
However, subsequent secondary injury is the main effect on
wound recovery after SWI, includes brain edema, hematoma,
and inflammatory and apoptotic responses, etc (Logsdon et al.,
2015). Although we have an improved understanding of the
pathophysiology that occurs in mechanical brain injury, clinical
neuroprotection trials that attempt to pharmacologically prevent
cellular death after mechanical brain injury have failed to show
consistent improvement in outcome for these patients. The lack
of effective therapy to repair injured brain tissue has motivated
researchers to focus on stem cells as a potential avenue for
regeneration, though much evidence of functional recovery was
provided by the use of exogenous stem cells in brain injury
in rodent models. However, there are still many questions
to be answered, including ethical and theoretical issues, the
appropriate source of stem cells, and immune rejection. Due to
the lack of effective therapies, the main clinical treatment is to
administer nerve nutrition and dehydration drugs, but the effect
is not ideal for injury and nervous system recovery. Inflammation
and apoptosis is a pathological hallmark of secondary injury of
SWI. The focus of modern medical treatment is to control and
reduce secondary damage. Seeds of Arctium lappa have been
used as a diuretic, anti-inflammatory and detoxifying agent in
Chinese traditional medicine. ARC, a bioactive phenylpropanoid
dibenzylbutyrolactone component lignin isolated from Arctium
lappa, has anti-inflammatory, and anti-apoptotic activities (Lee
et al., 2010; Tsai et al., 2011; Gu et al., 2012; Zhang N. et al.,
2013).
The release of inflammatory cytokines in cells after injury
is a normal immune response, but the overexpression of
some pro-inflammatory cytokines, such as IL-6 and TNF-a, are
detrimental to wound recovery (Zhai et al., 2015). A previous
study by Zhang et al. (2015) reports that ARC decreased
lipopolysaccharide (LPS)-induced acute lung inflammation,
infiltration of inflammatory cells into bronchoalveolar lavage
fluid, and production of pro-inflammatory cytokines. In other
reports, ARC had significantly decreased not only carrageenan-
induced paw edema but also MPO and eosinophil (EPO)
activities in arachidonic acid-induced edematous tissues (Kang
et al., 2008).
However, some anti-inflammatory cytokines, such as IL-10,
are beneficial to injury recovery (Zhai et al., 2015). Thus, a
drug that would increase favorable cytokines and reduce adverse
cytokines is best for disease recovery. Hyam et al. (2013) observed
that ARC not only peritoneal macrophages but also increased
LPS-reduced IL-10 and a cluster of differentiation (CD) 204
expression.
Many plant products have neuroprotective effects such as
osthole and ashwagandha. Osthole confers neuroprotection
against cortical SWI and attenuates secondary brain injury
(Xia et al., 2012). Ashwagandha and its constituent withanolide
A confers neuroprotection against β-amyloid and HIV-1Ba-L
(clade B) induced neuro-pathogenesis (Kurapati et al., 2013,
2014). These drugs are derived from traditional medicines which
have advantages on relatively minor toxic side effects and
long-term usage; it would be helpful to treat diseases of the
nervous system. ARC has been shown to act on scopolamine-
induced memory deficit mice and to provide a neuroprotective
effect on cultured cortical neurons. In our previous study, we
investigated the neuroprotective effect of ARC on H89-induced
cell damage and its potential mechanisms in mouse cortical
neurons and human SH-SY5Y neuroblastoma cells. We found
that ARC prevented cell viability loss and reduced intracellular
beta amyloid (Aβ) production induced by H89 in neurons
and human SH-SY5Y cells and also inhibited presenilin 1
(PS1) protein level in neurons. Our results showed that ARC
confers neuroprotective effects via upregulation of phospho-
cAMP response element binding protein (P-CREB) in mouse
primary neurons and human SH-SY5Y neuroblastoma cells.
The reduction of inflammation can contribute to nervous
system recovery, improving the neurological dysfunction caused
by the injury. A previous study has shown that ARC
treatment significantly reduced cerebral infarction and improved
neurological outcome through suppressing the activation of
microglia and decreasing the expression of IL-1β and TNF-α
(Fan et al., 2012).
The release of apoptotic cytokines is a major factor
affecting wound and neurological function recovery (Zhai et al.,
2015). Inflammation and apoptosis are closely related, and
inflammation can cause apoptosis (Fernandes-Alnemri et al.,
2009). Therefore, effective drugs can be both anti-inflammatory
and anti-apoptotic. In experimental Japanese encephalitis (JE)
treatment, ARC provided complete protection against disease.
ARC’s neuroprotective effect was associated with a marked
decreases in microgliosis and proinflammatory cytokines, active
caspase-3 activity and neuronal death. Furthermore, treatment
with ARC also improves the behavioral outcome following JE
(Swarup et al., 2008).
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FIGURE 1 | Structure of arctigenin (ARC) and CED system. (A) The chemical structure of ARC. (B) Coronal section of the mouse brain showing a schematic of
the needle track (in green). (C) Diagram of mouse model showing the CED system placement and site of stab in SWI brain injury. (D) Typical needle insertion force
vs. time for brain tissue. The insertion speed was 0.2 mm/s, and the insertion force was measured by digital force gage.
Based on the above studies, we assume that ARC treatment
can protect against brain damage via anti-inflammatory and anti-
apoptotic effects in a mouse model of CED-induced brain injury.
We observed neurological function, the BBB, inflammation and
apoptosis following a 2-week treatment with ARC. The results
suggest a new strategy for restoring neuronal function and
improving long-term patient outcomes after CED.
MATERIALS AND METHODS
Preparation of ARC
Arctigenin (catalog no. 140524, purity > 98% (Figure 1A) was
purchased from the Chengdu Puei De Biotech Co., Ltd (SIchuan,
China), dissolved in sodium carboxyl methyl cellulose (5% CMC)
(Kong et al., 2015), and stored at 4◦C.
Animals
Adult (25–30 g) C57BL/6J mice aged 3–4 months were
housed under a 12:12-h light/dark cycles with free access to
food and water. Animal procedures conformed to guidelines
set by Liaoning University of Traditional Chinese Medicine
Institutional Animal Care and Use Committee, which are in
accordance with those set by the National Institutes of Health
(Bethesda, MD, USA).
Model
A mouse model of SWI, as previously described in (Xia
et al., 2012; Hu et al., 2013; Gao et al., 2014) with slight
modifications, was created to mimic the CED procedure. Briefly,
anesthesia was initiated with chloral hydrate (4%, 0.1 ml/10 g)
delivered at 1.0 ml/min. The head was shaved and disinfected
with iodine/alcohol. Animals were fixed on an Autostereotaxic
Frame (PTW-1, Chengdu Instrument Factory, China). Body
temperature was maintained (37◦C) with a heating pad during
the entire procedure. The skull was exposed by a mid-sagittal
incision that began between the eyes and extended caudally to
the level of the ears to expose the bregma and lambda. A hole
of 2-mm diameter was drilled by hand into the skull above
the caudate putamen (CPu) over the left cerebral hemisphere.
Dura mater was carefully taken off, and any residual blood was
cleaned with phosphate–buffered saline (1 × PBS). A 20-gage,
1.5-mm diameter needle (Hamilton Company, Reno, NV, USA),
with a rigid core was inserted 2.5 mm lateral to the midline,
2.5 mm posterior to the lambdoidal suture, and at a depth of
4 mm from the surface of the brain (Figure 1B). The exposed
surface of the brain was kept wet with PBS during the course
of the experiment. The rigid core was then withdrawn, and
the needle was left in situ for 5 min before removal. The skin
was then sutured, and mice were allowed to recover in their
cages.
Needle Insertion and CED System
According to studies by Casanova et al. (2014a,b), a stainless
steel needle with a blunt tip was used in this study because
it has been used in clinical trials. To minimize tissue entering
the needle tip, the inner lumen of the needle was filled with
cyanoacrylate glue. To ensure the consistency of the experiment,
a linear stage (Figure 1D) was used to control needle insertion.
The needle was mounted on the Y-axis of the linear stage, and
mice were fixed on the heating pad with the metal frame to
position the mice under the needle. The X-axis and Z-axis of
the linear stage were adjusted such that drilled holes in the
rat skull were aligned with the needle tip. The Y-axis of the
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linear stage was adjusted such that the needle tip just reached
the brain, and subsequently, needles were inserted to a depth
of 4 mm into the brain. To reduce deviation, all processes of
needle insertion were controlled by a numerical control panel.
The dura mater is considered to be a tough membrane covering
that would add excessive surface deformation during needle
insertion. Thus, the dura mater was carefully removed before
needle insertion. Studies by Casanova et al. (2014a,b) indicated
that different speeds of needle insertion can produce different
pressures, which can induce different extents of damage. To
minimize the effects of speed and pressure changes during
insertion, a constant speed (0.2 mm/s) was used that produced
a stable pressure (0.029 ± 0.005 N) (Figure 1C). The insertion
force was measured by digital force gage (HF-2, Wenzhou
tripod instrument manufacturing CO., LTD, China). The digital
force gage monitored the process of insertion in real-time.
To reduce injury induced by infusion pressure, a low drug
infusion speed was used (2 µL/min). We assume that the
dosage of infusion was 10 µL, so the infusion process takes
approximately 5 min. Therefore, to mimic the drug delivery
process, the needle must stay in mice for 5 min after needle
insertion.
Drug Use
Mice were randomly divided into five groups (n = 6 each):
mice in groups 1–3 (SWI+ARC) were administered ARC
intragastrically (ig) 30 min after surgery at 20, 40, and
80 mg/kg dissolved in 5% CMC in PBS followed by once
daily intragastrical (ig) administration (200 µl) for the next
14 days; mice in the SWI control group were given 5% CMC
in PBS by intragastrical (ig) administration (200 µl) each day
for 14 days; and naïve C57BL/6J mice were used as controls.
Mice were sacrificed between 3 and 21 days post injury (dpi) for
analyses.
Assessment of Neurological Function
Neurological function was assessed with a modified NSS at
24 h and 3, 7, 14, and 21 dpi, as previously described (Lu
et al., 2003; Hirjak et al., 2013; Liu et al., 2014). The NSS
evaluation consisted of motor, sensory, reflex, and balance tests,
with results measured on a scale of 0–18 (0 = normal, 1–
6 = mild injury, 7–12 = mean-moderate injury; 13–18 = severe
injury, and 18 = maximal deficit). The test was administered
by blinded, trained investigators, and mice were familiarized
with the testing environment before being subjected to brain
injury.
Measurement of Brain Water Content
Brain water content was measured 3 days post-SWI. Following
decapitation, brains were harvested, and the cerebellum and
olfactory bulb was removed. Subsequently, surface liquid was
dried with filter paper. The brain wet weight was obtained on a
pre-weighed metal box after drying in an electric oven at 105◦C
for 24 h, and the percent water was calculated as (wet weight –
dry weight)/(wet weight) (Lee et al., 2008; Taya et al., 2010; Xia
et al., 2012).
Determination of Albumin Leakage and
Brain Hematoma
Blood–brain barrier permeability was determined by measuring
Evans blue (EB) extravasation (Bas¸kaya et al., 1997; Shi et al.,
2015). Four percent EB (4 mL/kg; Sigma–Aldrich) was injected
into the caudal vein at 3 dpi. One hour later, animals were
transcardially perfused with cold saline to remove intravascular
EB. The brains were removed carefully and visualized on a
OLYMPUS SZX9 microscope (Tokyo, Japan) with a digital
camera.
To quantify EB extravasation, each brain was carefully
weighed and soaked in methanamide for 48 h at 37.0◦C,
then subsequently centrifuged for 30 min at 20,000 g. The
absorption of the supernatant was measured at 632 nm with
a spectrophotometer (Bio-Rad, Hercules, CA, USA). Tissue
EB concentration was quantified using a standard curve and
expressed as µg/g of brain tissue.
Brain hematoma volume was determined by ImageJ
calculation of the area of congestion at 3 dpi. Mice were
anesthetized with chloral hydrate (4%, 0.1 ml/10 g) then were
transcardially perfused with 1% PBS to remove intravascular
blood. The brains were removed carefully and visualized on
a OLYMPUS SZX9 microscope (Tokyo, Japan) with a digital
camera.
Measurement of Lesion Size
At 3, 7, 14, and 21 dpi, mice were anesthetized and transcardially
perfused with 4% paraformaldehyde in cold phosphate buffer.
Brains were immediately harvested and visualized on a
OLYMPUS SZX9 microscope (Tokyo, Japan) with a digital
camera. The size of the wound lesion was measured in each brain
by tracing a line along the edge of the tissue lining the lesion with
ImageJ software (National Institutes of Health) (d’Avila et al.,
2012). Measurements were taken from 6 brains at each time
point.
Slice Preparation
Mice were anesthetized with 4% chloral hydrate (0.1 ml/10 g,
i.p.), and then transcardial perfusion with 1% PBS was performed.
Subsequently, 4% paraformaldehyde was perfused to fix tissue.
The brains were harvested and cryo-protected in PBS containing
30% sucrose until brains sank to the bottom. Then, the brains
were equilibrated to optimum cutting temperature compound
(OTC) and placed in the freezer. The brains were sectioned
into 5–10 mm thick sections with a cryostat (CM1900, Leica).
The sections were located in a direction parallel to the needle
penetration line at 150 µm intervals to cover the entire lesion
site. The sections were mounted on glass slides for staining and
visualized on a OLYMPUS SZX9 and BX51 microscope (Tokyo,
Japan) with a digital camera.
Nissl Staining
Seven days after SWI, the mouse brains (six per group) were
harvested and made into 5 µm slices for Nissl staining (Zhao
et al., 2014; Zhai et al., 2015). The sections were fixed in absolute
ethyl alcohol and then processed through different baths in the
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following order: 100% ethanol (1 min), 95% ethanol (1 min), 70%
ethanol (1 min), double distilled water (1 min, three times), cresyl
violet (56◦C, 1 h), double distilled water (1 min, three times),
neutral differentiation solution (2 min), 100% ethanol (1 min),
xylene (1 min); the samples were then mounted with neutral
balata and covered with a coverslip. The Nissl staining sections
were visualized on a OLYMPUS SZX9 and BX51 microscope
(Tokyo, Japan) with a digital camera.
Hematoxylin and Eosin (H&E) Staining
At 3 dpi, the mouse brains (six per group) were harvested and
made into 10 µm slices for H&E staining (Bitto et al., 2012;
Casanova et al., 2014a,b). The sections were dried for 30 min at
room temperature and then processed through different baths in
the following order: 70% ethanol (5 s), 80% ethanol (5 s), 95%
ethanol (5 s), distilled water (5 s, three times), hematoxylin (5 s,
three times), alcohol lamp heating (ten times), distilled water
(1 min, three times), 1% alcohol differentiation solution (3 s,
five times), distilled water (1 min, three times), 5% ammonia
(3 s, eight times), distilled water (1 min, three times), eosin (10
times), distilled water (1 min, three times), 70% ethanol (5 s),
80% ethanol (5 s), 95% ethanol (5 s), alcohol lamp heating; the
samples were then mounted with neutral balata and covered
with a coverslip. The H&E staining sections were visualized on
a OLYMPUS SZX9 microscope (Tokyo, Japan) with a digital
camera.
Immunofluorescent Staining
After SWI, the mice (six per group) were sacrificed at 3 days for
inflammation examination (Zhang R. et al., 2013) and 7 days for
apoptosis examination (Liu et al., 2014). Brains were harvested
and made into 5 µm slices for immunofluorescent staining.
The sections were processed through different baths in the
following order: 4% paraformaldehyde (30 min), 1% PBS (5 min,
three times), 1% Triton X-100 (30 min), 1% PBS (5 min, three
times), 5% bull serum albumin (BSA) (30 min), 1% PBS (5 min,
three times), primary antibody (Rabbit Anti-GFAP antibody,
Rabbit Anti-AIF1/Iba1 antibody, Rabbit Anti-MPO antibody,
Rabbit Anti-NF-M antibody, Rabbit Anti-Caspase-3 antibody)
(1:150, Abcam, Cambridge, MA, USA), incubation (4◦C, 12 h),
1% PBS (5 min, three times), secondary antibody (Donkey
Anti-rabbit IgG/Cy3 antibody, Donkey Anti-rabbit IgG/FITC
antibody) (1:200, Jackson ImmunoResearch Lab, West Grove, PA,
USA), incubation (protection from light, 1 h), 1%PBS (5 min,
three times), 4′,6-diamidino-2-phenylindole (DAPI) (protection
from light, 15 min), 1% PBS (5 min, three times); the samples
were then mounted with antifade mounting medium and covered
with a coverslip. The immunofluorescent staining sections were
visualized on a OLYMPUS SZX9 microscope (Tokyo, Japan) with
a digital camera.
TUNEL Staining
TUNEL Universal Apoptosis Detection Kit (Roche, Chicago, IL,
USA) was used for the fast detection of fragmented DNA in
the nucleus by red fluorescence probe labels during apoptosis.
Brain sections from mice at 7 dpi were analyzed for apoptotic
cells according to the manufacturer’s instructions. The number
of TUNEL-positive cells in each section in areas surrounding the
lesion were counted in six sections per mouse and six mice per
group using ImageJ software.
Analysis of Cytokine Levels by ELISA
Brains were collected at 3 dpi, and the tissue around the
cavity (diameter: 5 mm) weighing 100 mg was taken. Tissue
homogenates were obtained in 900 µL 1% PBS, and the
supernatant was stored at −80◦C. LDH (novus biologicals,
Littleton, USA, Cat. No. KA0878), TNF-α (Cat. No. MTA00B),
IL-6 (Cat. No. M6000B), and IL-10 (Cat. No.M1000B) levels
in the samples were measured using ELISA kits (R&D
Systems, Minneapolis, MN, USA) following the manufacturer’s
instructions (Xia et al., 2012).
Reverse Transcription (RT)-PCR
Total RNA was extracted from brain tissue at 3 and 7 dpi
with TRIzol reagent and reverse transcribed to cDNA using a
RevertAid First Strand cDNA Synthesis kit (Thermo Scientific,
Vilnius, Lithuania) (Yang et al., 2008). The PCR reaction (35
cycles) was performed using a DreamTaq Green PCR Master Mix
Kit (Thermo Scientific). Quantitative RT-PCR was performed
using the following forward and reverse primer sets designed
using Premier Biosoft 5 (Palo Alto, CA, USA): TNF-α, 5′-ATA
AGA GCA AGG CAG TGG AG-3′ and 5′-TCC AGC AGA
CTC AAT ACA CA-3′;IL-6, 5′-AGC CAG AGT CCT TCA GAG
AG-3′ and 5′-TCC TTA GCC ACT CCT TCT GT-3′; IL-10, 5′-
TTC TCA TTC CTG CTT GTG GC-3′ and 5′-ATC TGA GTG
TGA GGG TCT GG-3′; Bax, 5′-CTG ACA TGT TTT CTG ACG
GC-3′ and 5′-TCA GCC CAT CTT CTT CCA GA-3′; Bcl-2, 5′-
CGC TGG GAG AAC AGG GTA-3′ and 5′-GGG CTG GGA
GGA GAA GAT-3′; Caspase-3, 5′-AGA TAC CGG TGG AGG
CTG ACT-3′ and 5′-TCT TTC GTG AGC ATG GAC ACA-3′;
and β-actin (control), 5′-GGG AAA TCG TGC GTG ACA T-
3′ and 5′-TCA GGA GGA GCA ATG ATC TTG-3′. Products
were resolved by 1.5% agarose gel electrophoresis with ethidium
bromide staining. The mRNA levels of TNF-α, IL-6 and IL-10
were detected at 3 dpi, and those of Bax, Bcl-2, and caspase-3
were detected at 7 dpi. Quantitative analysis was performed using
a Tanon 4100 Gel Imaging System (Tanon Science & Technology
Co., Shanghai, China).
Measuring Cell Fluorescence Using
ImageJ
The fluorescent intensity was quantified by ImageJ, using
the follow steps: Select the cell of interest using any of
the drawing/selection tools (i.e., rectangle, circle, polygon, or
freeform); From the Analyze menu select “set measurements”.
Make sure that the AREA, INTEGRATED DENSITY, and MEAN
GRAY VALUE have been selected; Select “Measure” from the
analyze menu. A popup box will appear with a stack of values
for that first cell; Select a region next to the cell that has no
fluorescent, this will be located in the background; Repeat this
step for the other cells in the field of view that needs to be
measure; Once finished, select all the data in the Results window,
copy and paste into a new excel worksheet; Use this formula
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FIGURE 2 | Modified neurologic severity score and brain water content by ARC treatment. (A) Neurological function was analyzed by NSS at 1, 3, 7, 14,
and 21 days post injury (dpi). Treatment with ARC significantly lowered NSS from 3 to 21 dpi compared to untreated control. (B) Brain water content of injured
hemispheres was measured at 3 dpi. The untreated SWI group had a significantly higher brain water content than naive control. ARC treatment significantly reduced
brain water contents in a dose-dependent manner. n = 6 per group. The data are presented as the mean ± SD. ##P < 0.01 vs. naive control; ∗P < 0.05,
∗∗P < 0.01, vs. SWI control.
to calculate the corrected total cell fluorescence (CTCF). More
details of the operation can be viewed in the ImageJ’s instructions
on Measuring Cell Fluorescence.
Statistical Analysis
The data were analyzed using SPSS version 13.0 (SPSS, Chicago,
IL, USA) and are presented as the mean ± SD. Differences
between groups were assessed by one-way analysis of variance,
and post hoc multiple comparisons were performed with
the Student-Newman–Keuls test. P < 0.05 was considered
statistically significant.
RESULTS
In the present study, we use naïve (uninjured) mice as controls
rather than those subjected to craniotomy. In a previous
study, minor injury craniotomy was shown to induce acute
inflammatory response (Bayir et al., 2003; Cole et al., 2011). After
craniotomy, mice had similar numbers of glial fibrillary acidic
protein (GFAP)-positive astrocytes compared to experienced
moderate cortical impact injury mice (Susarla et al., 2014).
ARC Treatment Improves Neurological
Function after SWI
To determine whether ARC has neuroprotective effects after
SWI, the curative effect of different concentrations of ARC (20,
40, or 80 mg/kg/day) were evaluated using an NSS system. NSS
was evaluated from 1 to 21 dpi. As shown in Figure 2A, ARC
treatment improves neurological function from 3 to 21 days
compared to naïve control mice. ARC treatment decreased the
NSS in a dose-dependent manner, and the administration of a
high dose (80 mg/kg) decreased the NSS the most significantly
compared to the middle and low dose. At 3 dpi, we observed
that ARC showed a certain treatment effect of decreasing the
NSS in various concentrations, but no significant difference was
found between ARC-treated and SWI control group. Regarding
7 dpi, the treatment effect of ARC increased remarkable and had
significant difference (7.25 ± 1.04 vs. 9.00 ± 0.93; P < 0.05 vs.
SWI control at 7 dpi) between the highest dose group and that
of SWI control. The treatment effect increased until 21 dpi in
various concentrations (3.38 ± 1.06 vs. 5.50 ± 0.75; P < 0.01 vs.
SWI control at 21 dpi).
ARC Treatment Decreases Brain Edema
Caused by Injury
Brain edema is caused by damage of the BBB after TBI, and
brain water content increase is a marker for brain damage
(Zhang R. et al., 2013). A second opening of the BBB will
occur due to the inflammation response at 3 dpi (Bas¸kaya et al.,
1997). In the present study, different concentrations of ARC
were tested to determine whether treatment can lower the brain
water content by reducing the inflammatory response 3 days
after injury. As shown in Figure 2B, the highest brain water
content was in the SWI compared to the naïve control and
administration group (79.23% ± 0.27% vs. 77.91% ± 0.19%);
ARC treatment decreased the brain water content in a dose-
dependent manner, and the most significant decrease was
observed with 80 mg/kg ARC (78.29%± 0.24%; P< 0.01 vs. SWI
control).
ARC Treatment Accelerates Wound
Healing after SWI
The most direct way to analyze wound healing is to observe
the wound size in the brain cavity caused by needle insertion.
The size of the brain cavity was measured at four different time
points (3, 7, 14, and 21 dpi) after injury. As shown in Figure 3A,
the size of the brain cavity gradually becomes smaller with the
passage of time, but the size of the ARC treatment group is
smaller than SWI control mice at each time point. Cavity size
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FIGURE 3 | Decreased wound cavity size in mice treated with ARC. (A) Representative images of mouse brains at 3, 7, 14, and 21 dpi. (B) The graph shows
the areas of wound cavities measured as described in the Section “Materials and Methods”. The cavity areas in ARC-treated mice from 3 to 21 dpi were significantly
smaller than those in the untreated control. The wound cavity is shown at higher magnifications in the insets. Measurements were taken from 6 brains and 6 mice
per time point. The data are presented as the mean ± SD. ∗P < 0.05, ∗∗P < 0.01, vs. SWI control. Scale bar: 5 mm.
was smallest at 21 dpi in ARC-treated mice, and thus, ARC
treatment accelerates wound healing after SWI. By 21 dpi, the
cavity was smallest in 3/6 ARC-treated mice vs. 5/6 untreated
controls (0.033± 0.0041 mm2 vs. 0.070± 0.0054 mm2; P< 0.05)
(Figures 3A,B).
ARC Treatment Decreases Albumin
Leakage and Brain Hematoma Caused
by Injury
Traumatic brain injury can inflict devastating effects to the
brain vasculature and neighboring neuronal cells. Vasculature
disruption and increased BBB permeability are primary effects
that can lead to a host of secondary injury cascades (Logsdon
et al., 2015). Primary damage of the BBB leads to brain
hemorrhage and Albumin Leakage, which occur immediately
after TBI, and a second opening of the BBB will occur due
to the inflammation response at 3 dpi (Bas¸kaya et al., 1997).
In this study, EB leakage was tested to determine whether
ARC treatment preserves BBB integrity via anti-inflammatory
effects after SWI. As shown in Figures 4B,D, the volume of
EB extravasation was significantly decreased in ARC-treated
mice compared to SWI control mice (EB: 2.64 ± 0.36 µg/g
vs. 5.47 ± 0.64 µg/g; P < 0.05). If ARC treatment protects
BBB integrity, the volume of brain hemorrhage should also
reduce. Consistent with this, brain hematomas were detected,
and the result in Figures 4A,C shows that the volume of brain
hematoma was significantly decreased in ARC-treated compared
to SWI control mice (1.56 ± 0.26 mm2 vs. 2.35 ± 0.25 mm2;
P < 0.05).
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FIGURE 4 | Arctigenin treatment preserves BBB integrity and blood exudation after SWI. (A) Representative images of the congestion area of the brain at
3 dpi after SWI. Yellow lines delimit the congestion area. The area of congestion was reduced in the ARC- treated SWI brain compared to the untreated brain.
(B) Representative images of EB-stained brain at 3 dpi after SWI. The EB-stained areas were reduced in ARC-treated SWI brain compared to the untreated brain.
(C) Quantitative results of the congestion area (n = 6/group) calculated by Image J software. (D) Quantitative results of EB extravasation in each brain (n = 6/group),
expressed as EB content (µg/g) calculated from a standard curve. The data are presented as the mean ± SD. ##P < 0.05 vs. naive control; ∗∗P < 0.01, vs. SWI
control. Scale bar: 0.5 mm in (A), 5 mm in (B).
ARC Treatment Suppresses the
Inflammatory Response Caused by Injury
Lactate dehydrogenase (LDH) was used to evaluate the extent
of cell damage. LDH is released during tissue damage and is a
marker of common injuries. The brain tissue broke down and
neural cells were damaged after SWI (Zhao et al., 2012), and
then the damaged cells released inflammatory cytokines (Zhang
et al., 2012; Gao et al., 2014). Pro-inflammatory cytokines can
activate astrocytes, and in turn, activated astrocytes release pro-
inflammatory cytokines such as IL-6 and TNF-α (Lau and Yu,
2001; Ziebell and Morganti-Kossmann, 2010). Macrophages and
neutrophils act as the first and main forms of active immune
defense, and microglia are a type of glial cells that are the
resident macrophages in the brain. After TBI, neutrophils and
microglia were activated, and this was the main feature of
neuroinflammation (Wang et al., 2007; Clausen et al., 2009).
Microglia can also release IL-6 and TNF-α. At 3 days after injury,
a large number of inflammatory cytokines were released, and a
large number of inflammatory cells were activated (Figure 5A).
Thus, the time point 3 dpi was chosen to test the role of ARC
in the inflammatory response (Xia et al., 2015). As shown in
Figures 5B–D, the numbers of Iba-1+ macrophages/microglia
and MPO+ neutrophils in the lesioned cortex significantly
decreased in the ARC treatment group compare to the untreated
group; however, the numbers of GFAP+ astrocytes did not
change, and there was no significant difference in the results of
the experiment. (GFAP+: 217.33 ± 35.30 vs. 219.311 ± 42.96
cells/mm2; Iba-1+: 115.33± 47.96 vs. 247.83± 52.29 cells/mm2;
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FIGURE 5 | Reduced inflammatory cell infiltration and pro-inflammatory cytokine levels as a result of ARC treatment. (A) Illustration of the spatial
distribution of inflammatory cells. The cells were distributed around the lesion at 3 dpi. (B–D) Images of GFAP+, Iba-1+, and MPO+ cells by immunohistochemistry
in a single field (box) in the lesioned cortex. Macrophages/microglia (Iba-1+ green), neutrophils (MPO+, red) and astrocytes (GFAP+, red) with nuclear DAPI staining
(blue). (E) LDH was measured to evaluate the extent of cell damage. (F–H) Quantification of the inflammatory cells among the total number of cells (DAPI+). All
groups were examined in the regions immediately surrounding the lesion. Boxed areas appear at higher magnifications in the insets. Scale bar: 5 mm in (A), 50 µm
in (B–D). (I–K) Levels of the proinflammatory cytokines IL-6, TNF-α, and IL-10 assessed by ELISA assay. The data are presented as the mean ± SD, n = 6 per
group. ##P < 0.01 vs. naive control; ∗P < 0.05, ∗∗P < 0.01, vs. SWI control.
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MPO+: 256.67 ± 61.99 vs. 309.06 ± 52.67 cells/mm2,
P < 0.01) (Figures 5F–H). We also measured the levels of pro-
inflammatory cytokines (IL-6 and TNF-α) and anti-inflammatory
cytokines (IL-10) in cortical tissue homogenates by ELISA at
3 dpi. As shown in Figures 5E,I,J,K, ARC reduced the levels
of LDH and pro-inflammatory cytokines TNF-α and IL-6 and
increased the level of IL-10 in ARC-treated relative to untreated
control animals (LDH: 1.13 ± 0.087 vs. 1.24 ± 0.15; TNF-α:
17.78 ± 0.55 vs. 18.93 ± 0.68 pg/100 mg; IL-6: 5.71 ± 0.041 vs.
11.47 ± 0.054 pg/100 mg; IL-10: 32.60 ± 0.068 vs. 25.85 ± 0.079
pg/100 mg; P < 0.01).
ARC Treatment Reduces Apoptosis and
Increases Neuronal Survival in the
Injured Brain
The physical forces of TBI can shear axons (Raghupathi and
Margulies, 2002) and break down neurons and its neighboring
cells (Figure 6A), eventually resulting in axon loss and neuron
and cell death (Clark et al., 1997). The most serious cell death
occurred at 7 days after injury, and thus the time point 7 dpi
was chosen to examine the role of ARC in the apoptotic response
(Xia et al., 2015). To assess the effects of ARC treatment at
the cellular level, brain sections were tested for Nissl staining
(Figures 6B,F) and neurofilament medium polypeptide (NF-M)
expression (Figures 6C,G) at 7 dpi, and apoptotic cells were
detected by the TUNEL assay (Figures 6E,I) and by examining
caspase-3 expression (Figures 6D,H). As Nissl stained images
show in Figure 6B, the number of neuronal cells increased
significantly in the ARC treatment group compared to untreated
mice (Nissl+:113.17 ± 12.60 vs.105.34 ± 10.51) (Figure 6F).
Axons decreased significantly in SWI control mice and resulted
in lowered expression of NF-M. However, ARC treatment
increased expression of NF-M in treated mice (Figure 6C).
(fluorescence intensity: 75.55 ± 10.36 vs. 62.91 ± 8.32; P < 0.05)
(Figure 6G). The number of TUNEL+ and caspase-3+ cells
decreased significantly in the ARC-treated lesion area compared
to untreated controls (TUNEL+: 84.25± 17.99 vs. 129.03± 23.73
cells/mm2; caspase-3+: 72.58 ± 14.54 vs. 124.81 ± 16.72
cells/mm2; P < 0.05) (Figures 6D,E,H,I). Thus, ARC promotes
neuronal recovery by inhibiting apoptosis after SWI.
ARC Treatment Suppresses the
Inflammatory Response and Inhibits
Apoptosis at the Gene Level
To clarify the potential mechanisms of anti-inflammatory and
anti-apoptotic functions of ARC, we determined the levels of
mRNA expression of pro-inflammatory cytokines (TNF-α, IL-
6) and anti-inflammatory cytokine IL-10 and apoptotic factors
caspase-3, Bax and Bcl-2 by RT-PCR. As shown in Figure 7A,
SWI induced an increase in TNF-α, IL-6, IL-10, Bax, and
Caspase-3 and a decrease in Bcl-2 transcription. ARC treatment
resulted in downregulation of TNF-α, IL-6 and caspase-3, a
reduction in the ratio of Bax to Bcl-2 and upregulation of IL-10
compared to the untreated SWI group (TNF-α: 0.165 ± 0.009
vs. 0.204 ± 0.015; IL-6: 0.241 ± 0.016 vs. 0.283 ± 0.018; IL-
10: 0.221 ± 0.012 vs. 0.139 ± 0.012; caspase-3: 0.117 ± 0.010
vs. 0.012 ± 0.06; Bax to Bcl-2 ratio: 0.499 ± 0.083 vs.
1.823± 0.165; P < 0.01) (Figures 7B–F). Thus, ARC exerts anti-
inflammatory effects via inhibition of TNF-α and IL-6 expression
and promotion of IL-10 expression and confers anti-apoptotic
effects by reducing the Bax to Bcl-2 ratio and downregulating
caspase-3 expression.
DISCUSSION
After CED, the brain will be damaged by penetration as
TBI. Following TBI, there are immediate primary effects and
subacute secondary effects. Primary effects to the brain from TBI
cause damage to neurons, glia, normal cells, and the cerebral
vasculature. Secondary effects to the brain from TBI include
inflammatory responses (Farook et al., 2013), cellular stress (Xia
et al., 2015), apoptotic cascades (Clark et al., 1997), and loss
of axons (Raghupathi and Margulies, 2002). Secondary effects
are the main factors that affect the recovery of damage in later
stages and are caused by primary effects. In this study, we mainly
investigated the secondary injury treatment of ARC after CED.
In an animal model, we mimicked the procedure of CED
by using a needle to create a SWI in the mouse brain and
investigated whether ARC treatment could protect against
secondary brain damage. In this study, ARC protected against
BBB damage, reduced the number of microglia/macrophages in
the brain cortex, decreased the number of peripheral infiltrating
leukocytes at the lesion, reduced proinflammatory cytokine
levels, increased anti-inflammatory cytokine levels, and inhibited
apoptosis. These effects were exerted via upregulation of IL-10
and downregulation of IL-6, TNF-α, and caspase-3 expression
and a reduction in the ratio of Bax to Bcl-2 at gene level.
Thus, ARC can prevent secondary brain damage through anti-
inflammatory as well as anti-apoptotic mechanisms.
Cerebral hemorrhage and cerebral edema occurred after
CED due to the severely damaged BBB. Previous studies have
indicated that the occurrence of cerebral hemorrhage is followed
by BBB, which is a universal and crucial pathophysiological
change (Kastrup et al., 2008). Intracerebral hemorrhage can
lead to serious brain tissue damage, such as cerebral hematoma
after disruption of the BBB. The level of severity of hematoma
is closely related to the clinical prognosis of patients (Wang,
2010; Loftspring et al., 2011; Moxon-Emre and Schlichter,
2011). In this study, we investigated the brain water content,
the BBB permeability and the brain hematoma volume as a
result of ARC treatment at 3 dpi. The results showed that
ARC treatment protected against BBB damage by reducing
the brain water content, the BBB permeability and the
volume of brain hematomas. The BBB will open again at
3 dpi due to the inflammatory response (Bas¸kaya et al.,
1997). In previous studies (Zhao et al., 2009; Kou et al.,
2011) and this study, results indicate that ARC confers anti-
inflammatory effects, which is the potential mechanism of BBB
protection.
After TBI, the damaged cells released LDH and
inflammatory cytokines that can cause neuroinflammation.
Neuroinflammation is characterized by macrophage and
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FIGURE 6 | Promoted neuronal survival and reduced apoptosis in lesioned brains of mice as a result of ARC treatment. (A–C) Survival of neurons in the
lesioned cortex of mice were stained with Nissl and anti-NF-M antibodies. (D,E) Apoptotic cells were detected by caspase-3 immunostaining and TUNEL assay on
serial sections of the brain at 7 dpi. (B,F) Areas positive for Nissl antibody were revealed by Nssl staining. (C,G) Areas negative for NF-M were revealed by
immunohistochemistry. (D,H) Apoptotic neurons were immunostained with anti-caspase-3+ antibodies. (E,I) Apoptotic cells were determined by TUNEL assay. The
amount of NF-M expression around the lesions was quantified by measurement of pixel intensity of NF-M immunoreactivity by measurement of pixel intensity of
NF-M immunoreactivity using Image J software. The amount of other positive expression around the lesions was quantified by measurement of number of positive
cells using ImageJ software. Boxed areas appear at higher magnifications in the insets. Scale bar: 5 mm in A, 50 µm in (B–E). Nuclei were stained with DAPI (blue).
All groups were examined within the areas immediately surrounding the lesion. The data are presented as the mean ± SD, n = 6 per group. ##P < 0.01 vs. naive
control; ∗P < 0.05, ∗∗P < 0.01, vs. SWI control.
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FIGURE 7 | Changes of gene expression in injured brain after ARC administration. Total RNA was extracted from injured brain tissue at 3 and 7 dpi. mRNA
expression of IL-6, IL-10 and TNF-α was examined at 3 dpi, and Bax, Bcl-2, and Caspase-3 were examined at 7 dpi. (A) mRNA expression revealed by RT-PCR.
(F) Quantitative analysis of the ratio of Bax/Bcl-2. (B–E) Quantitative analysis of mRNA Levels of TNF-α, IL-6, IL-10, and Caspase-3. ARC administration up-regulated
mRNA expression of IL-10, down-regulated mRNA expression of TNF-α, IL-6, and Caspase-3, and reduced the ratio of Bax to Bcl-2 significantly compared to the
untreated control. The data are presented as the mean ± SD, n = 6 per group. ##P < 0.01 vs. naive control; ∗P < 0.05, ∗∗P < 0.01, vs. SWI control.
neutrophil infiltration and microglia activation after brain
injury (Wang et al., 2007; Clausen et al., 2009). The number
of neuroinflammatory cells can predict the extent of brain
recovery. However, the term neuroinflammation generally
refers to more chronic, sustained injury while the responses of
microglial cells contribute to and expand the neurodestructive
effects, worsening the disease process (Streit, 2006). Microglia
can activate the proinflammatory cytokines IL-1α, IL-1β, and
TNF-α in the CNS (Wood, 2003). Proinflammatory cytokines
such as TNF-α and IL-6 are mainly produced by microglia, which
in turn activate glia, further stimulating cytokine production
and astrogliosis (Lau and Yu, 2001; Ziebell and Morganti-
Kossmann, 2010; Xia et al., 2012). In a previous report, ARC
had significantly decreased MPO and EPO activities in injury
tissues (Kang et al., 2008). Thus, in previous studies and
in this study, results suggest that ARC suppresses trauma-
induced inflammation by inhibiting microglia activation and
neutrophil infiltration as well as the release of proinflammatory
cytokines that can cause secondary damage to the brain after
injury.
The expression of inflammatory cytokines TNF-α, IL-6,
and IL-10 was upregulated after injury. TNF-α and IL-6 are
proinflammatory cytokines (Wilson et al., 2005), and IL-10
is anti-inflammatory cytokine. Transgenic mice overexpressing
IL-6 show enhanced neuroinflammation and brain damage
(Campbell et al., 1993). TNF-α is a key cytokine in the
inflammatory response caused by tissue destruction, bacterial
infection and tumor cells (Aggarwal et al., 1985), and it can
induce the occurrence of and worsen inflammation (Chen
et al., 2006). The most important function of IL-10 is to
limit and eventually terminate the inflammatory response
(Moore et al., 2001). In vitro, IL-10 can significantly decrease
the secretion of proinflammatory cytokines, such as TNF-
α (Schmit et al., 2001). The data from Cuzzocrea et al.
indicate that the reduction of TNF-α and IL-6 results in a
decrease of secondary tissue injury (Genovese et al., 2008).
In a previous study, ARC potently inhibited nitric oxide
(NO), TNF-α and IL-6, but not cyclooxygenase (COX)-
2 expression and COX-2 activity, possibly constituting the
anti-inflammatory mechanism of ARC (Zhao et al., 2009).
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The data from Kou et al. (2011) shows that ARC exerts its
anti-inflammatory effect by inhibiting reactive oxygen species
(ROS)-dependent signal transducer and activator of transcription
(STAT) signaling through its antioxidant activity. ARC also
significantly reduced the phosphorylation of STAT1, STAT3,
and JAK2 in LPS-stimulated RAW264.7 cells (Kou et al.,
2011). ARC not only inhibited LPS-increased IL-6 and TNF-
α expression in LPS-stimulated peritoneal macrophages but
also increased LPS-reduced IL-10 and CD 204 expression
(Hyam et al., 2013). Hence, excessive IL-6 and TNF-α-mediated
inflammation is likely involved in the unfavorable outcomes
associated with SWI. Based on the above data and these studies,
ARC treatment partly blocks the increase in IL-6 and TNF-α
expression and promotes the increase in IL-10 expression at the
molecular and gene level as a result of brain injury, providing
additional evidence that ARC suppresses neuroinflammation
via downregulation of IL-6 and TNF- a and upregulation of
IL-10.
The Nissl (Nissl, 1894) body is a type of alkaline substance
that is widely distributed in various neurons, and it can be
seen in the soma and dendrites of neurons though not in
the axon or axon hillock (Thompson, 2000; Kühnel, 2003).
Upon neuron damage, the number of Nissl bodies can be
reduced or even disappear, thus the degree of damage of
neurons can be observed by observation of the Nissl body (Zhao
et al., 2014; Zhai et al., 2015). NFs are the most abundant
cytoskeletal proteins in large myelinated axons (Hozumi et al.,
1990; Perrot et al., 2008); specifically, NF-M is important
for the stabilization of mature axons (Wood, 2003). NF-M
expression is decreased in injured animals, indicating axonal
loss. Neuron structure (perikaryon, axon, dendrite) will be
destroyed after CED, leading to secondary injury. Secondary
pathophysiological insults will cause delayed neuronal death
in surrounding or distant regions (Stoica and Faden, 2010).
We observed the number of Nissl staining neurons and NF-
M expression around the cavity in injured animals, results
show that ARC treatment increases the number of neurons
and NF-M expression compared to untreated animals, providing
structural evidence for the effects of ARC in promoting
neuronal restoration and inhibiting apoptosis in the injured
brain.
Caspase-3 is a caspase protein that is encoded by the CASP3
gene. Caspase-3 is activated in the apoptotic cell both by
the extrinsic (death ligand) and the intrinsic (mitochondrial)
pathways (Salvesen, 2002; Ghavami et al., 2009), and caspase-
3 activity induces apoptosis and will kill cells indiscriminately
(Li et al., 1997; Boatright and Salvesen, 2003). The Bcl-2
family includes genes encoding the anti-apoptotic protein Bcl-
2 and the pro-apoptotic protein Bax (Youle and Strasser, 2008;
Kotipatruni et al., 2011). Bax overexpression stimulates apoptosis
and suppresses the recovery of injury (Gross et al., 1998),
while the overexpression of Bcl-2 inhibits neuronal apoptosis
and promotes the recovery of neurological function (Allsopp
et al., 1993; Fan et al., 2010). Bax upregulation and Bcl-2
downregulation increases the Bax to Bcl-2 ratio; this may be
directly associated with cytochrome c release (Adams and Cory,
1998). In this study, ARC treatment reduced the Bax to Bcl-2
ratio and caspase-3 levels compared to untreated mice, providing
insight into the mechanism underlying the anti-apoptotic effects
of ARC.
Apoptosis is the process of programmed cell death (PCD)
(Green, 2011). A form of traumatic cell death that results
from acute cellular injury, apoptosis is a highly regulated and
controlled process that confers advantages during an organism’s
lifecycle. However, excessive apoptosis causes atrophy. Among
the induction of apoptosis, inflammation plays an important
role (Saal, 1995; Lucas et al., 2006). TNF-α is a cytokine
mainly produced by activated macrophages and is the major
extrinsic mediator of apoptosis (Harper et al., 2003; Yan et al.,
2013). IL-6 is a pro-inflammatory cytokine that can also
induce cell death (Yao et al., 2015), While IL-10 is an anti-
inflammatory cytokine, it can also inhibit cellular apoptosis
(Banz et al., 2002). In previous reports, ARC was shown to
confer neuroprotective effects through anti-inflammatory and
anti-apoptotic effects (Swarup et al., 2008). In the present study,
we investigated the number of dead cells using a TUNEL
assay and capsase-3 expression around the cavity in injured
animals. The results show that ARC treatment decreases the
number of TUNEL+ and caspase-3+ expressing cells compared
to untreated animals, providing anti-inflammatory and anti-
apoptotic evidence for the effects of ARC in promoting neuronal
protection in the injured brain. Thus, we conclude that the
underling mechanism of apoptosis inhibition of ARC occurs
through an anti-inflammatory process.
CONCLUSION
Arctigenin treatment protects against BBB damage and
secondary brain injury via anti-inflammatory and anti-apoptotic
mechanisms in an experimental cortical SWI model. This study
demonstrates that ARC confers neuroprotection and improves
long-term neurological outcomes after CED.
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